• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

墨西哥一所大学的学生使用次水杨酸铋对症治疗腹泻。

Symptomatic treatment of diarrhea with bismuth subsalicylate among students attending a Mexican university.

作者信息

DuPont H L, Sullivan P, Pickering L K, Haynes G, Ackerman P B

出版信息

Gastroenterology. 1977 Oct;73(4 Pt 1):715-8.

PMID:330307
Abstract

Students attending a Mexican university who developed diarrhea were randomly treated with bismuth subsalicylate or a placebo. One hundred and eleven were given 30 ml each 1/2 hr until eight doses (total dose of active drug 4.2 g) were given and 58 students received twice this dose (8.2 g of active drug) over the 3 1/2-hr treatment period. The number of unformed stools was significantly decreased in both bismuth subsalicylate treatment groups compared to the placebo controls for the period 4 to 24 hr after therapy. A reduction in diarrhea was additionally noted for the duration of the 48-hr surveillance period for the students receiving the higher dose of active drug. Subjective relief within 24 hr of therapy of the symptoms of diarrhea, nausea, and abdominal pain or cramps was reported with a significantly increased frequency in the bismuth subsalicylate group. The most pronounced effect of the treatment occurred in the United States students with diarrhea who had recently arrived in Mexico. This appeared to be related to the favorable effect of bismut subsalicylate on the course of toxigenic Escherichia coli infection. Students with shigellosis did not experience a prolonged illness in either treatment group.

摘要

就读于墨西哥一所大学且出现腹泻症状的学生被随机给予碱式水杨酸铋或安慰剂进行治疗。111名学生每半小时服用30毫升,直至服用八剂(活性药物总剂量4.2克),58名学生在3个半小时的治疗期内服用两倍剂量(8.2克活性药物)。与安慰剂对照组相比,在治疗后4至24小时期间,两个碱式水杨酸铋治疗组的不成形粪便数量均显著减少。对于接受较高剂量活性药物的学生,在48小时监测期内腹泻情况也有所减轻。碱式水杨酸铋组报告在治疗24小时内腹泻、恶心以及腹痛或痉挛症状主观缓解的频率显著增加。治疗效果最显著的是刚抵达墨西哥且患有腹泻的美国学生。这似乎与碱式水杨酸铋对产毒性大肠杆菌感染病程的有利影响有关。在两个治疗组中,患志贺氏菌病的学生病程均未延长。

相似文献

1
Symptomatic treatment of diarrhea with bismuth subsalicylate among students attending a Mexican university.墨西哥一所大学的学生使用次水杨酸铋对症治疗腹泻。
Gastroenterology. 1977 Oct;73(4 Pt 1):715-8.
2
Double-blind comparison of bismuth subsalicylate and placebo in the prevention and treatment of enterotoxigenic Escherichia coli-induced diarrhea in volunteers.次水杨酸铋与安慰剂预防和治疗志愿者肠毒素性大肠杆菌所致腹泻的双盲比较
Gastroenterology. 1983 Nov;85(5):1017-22.
3
Prevention of traveler's diarrhea (emporiatric enteritis). Prophylactic administration of subsalicylate bismuth).旅行者腹泻(旅行性肠炎)的预防。(碱式水杨酸铋的预防性给药)
JAMA. 1980 Jan 18;243(3):237-41.
4
Treatment of travelers' diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone.用甲氧苄啶/磺胺甲恶唑和单用甲氧苄啶治疗旅行者腹泻。
N Engl J Med. 1982 Sep 30;307(14):841-4. doi: 10.1056/NEJM198209303071401.
5
Nonfluid therapy and selected chemoprophylaxis of acute diarrhea.急性腹泻的非液体疗法及特定化学预防措施
Am J Med. 1985 Jun 28;78(6B):81-90. doi: 10.1016/0002-9343(85)90369-9.
6
Prevention of travelers' diarrhea by the tablet formulation of bismuth subsalicylate.次水杨酸铋片剂预防旅行者腹泻
JAMA. 1987 Mar 13;257(10):1347-50.
7
Comparison of loperamide with bismuth subsalicylate for the treatment of acute travelers' diarrhea.洛哌丁胺与碱式水杨酸铋治疗急性旅行者腹泻的比较。
JAMA. 1986 Feb 14;255(6):757-60.
8
Evaluation of bismuth subsalicylate in relieving symptoms of indigestion.碱式水杨酸铋缓解消化不良症状的评估。
Arch Intern Med. 1984 Feb;144(2):269-72.
9
Comparative efficacy of loperamide hydrochloride and bismuth subsalicylate in the management of acute diarrhea.盐酸洛哌丁胺与碱式水杨酸铋治疗急性腹泻的疗效比较
Am J Med. 1990 Jun 20;88(6A):15S-19S. doi: 10.1016/0002-9343(90)90270-n.
10
Prevention of diarrhea caused by enterotoxigenic Escherichia coli: lessons learned with volunteers.预防产肠毒素大肠杆菌引起的腹泻:志愿者研究所得经验教训
Rev Infect Dis. 1990 Jan-Feb;12 Suppl 1:S68-72. doi: 10.1093/clinids/12.supplement_1.s68.

引用本文的文献

1
The Role of Purported Mucoprotectants in Dealing with Irritable Bowel Syndrome, Functional Diarrhea, and Other Chronic Diarrheal Disorders in Adults.所谓黏液保护剂在治疗成人肠易激综合征、功能性腹泻和其他慢性腹泻疾病中的作用。
Adv Ther. 2021 May;38(5):2054-2076. doi: 10.1007/s12325-021-01676-z. Epub 2021 Mar 18.
2
Systematic Review and Meta-Analyses Assessment of the Clinical Efficacy of Bismuth Subsalicylate for Prevention and Treatment of Infectious Diarrhea.系统评价和荟萃分析评估次水杨酸铋预防和治疗感染性腹泻的临床疗效。
Dig Dis Sci. 2021 Jul;66(7):2323-2335. doi: 10.1007/s10620-020-06509-7. Epub 2020 Aug 8.
3
Effect of Bismuth Subsalicylate vs Placebo on Use of Antibiotics Among Adult Outpatients With Diarrhea in Pakistan: A Randomized Clinical Trial.
铋剂与安慰剂对巴基斯坦成人腹泻门诊患者抗生素使用的影响:一项随机临床试验。
JAMA Netw Open. 2019 Aug 2;2(8):e199441. doi: 10.1001/jamanetworkopen.2019.9441.
4
Guideline for the Antibiotic Use in Acute Gastroenteritis.急性胃肠炎抗生素使用指南。
Infect Chemother. 2019 Jun;51(2):217-243. doi: 10.3947/ic.2019.51.2.217.
5
Management of Acute Diarrheal Illness During Deployment: A Deployment Health Guideline and Expert Panel Report.部署期间急性腹泻病的管理:一份部署健康指南及专家小组报告。
Mil Med. 2017 Sep;182(S2):34-52. doi: 10.7205/MILMED-D-17-00077.
6
ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults.ACG 临床指南:成人急性腹泻感染的诊断、治疗和预防。
Am J Gastroenterol. 2016 May;111(5):602-22. doi: 10.1038/ajg.2016.126. Epub 2016 Apr 12.
7
Travellers' diarrhoea.旅行者腹泻
BMJ Clin Evid. 2015 Apr 30;2015:0901.
8
Antimicrobial activity of bismuth subsalicylate on Clostridium difficile, Escherichia coli O157:H7, norovirus, and other common enteric pathogens.次水杨酸铋对艰难梭菌、大肠杆菌O157:H7、诺如病毒及其他常见肠道病原体的抗菌活性。
Gut Microbes. 2015;6(2):93-100. doi: 10.1080/19490976.2015.1008336.
9
Zinc protects against Shiga-toxigenic Escherichia coli by acting on host tissues as well as on bacteria.锌通过作用于宿主组织和细菌来抵御产志贺毒素大肠杆菌。
BMC Microbiol. 2014 Jun 5;14:145. doi: 10.1186/1471-2180-14-145.
10
Oral bismuth for chronic intractable diarrheal conditions?口服铋剂治疗慢性顽固性腹泻?
Clin Exp Gastroenterol. 2013;6:19-25. doi: 10.2147/CEG.S41743. Epub 2013 Mar 13.